Dark

Check out our Dark Pool Levels

NGM
NGM Biopharmaceuticals, Inc. Common Stock
stock NASDAQ

Inactive

Apr 4, 2024

1.54USD-1.282%(-0.02)2,390,830

Pre-market

0.00USD-100.000%(-1.56)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 20, 2022

08:00AM EST NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the following upcoming virtual investor conferences. GlobeNewswire Inc

Jan 10, 2022

09:00AM EST NGM Bio Outlines 2022 Strategic Priorities Across Its Portfolio of GlobeNewswire Inc

Jan 6, 2022

08:00AM EST NGM Bio to Present at 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc

Dec 6, 2021

08:24AM EST CORRECTION: NGM Biopharmaceuticals Was Tagged In Superior Group Of Companies News By Error Benzinga

08:23AM EST BAMKO Acquires Sutter's Mill Specialties For ~$24.5M Benzinga

08:06AM EST CORRECTION: NGM Biopharmaceuticals Ticker Is 'NGM' Benzinga

08:05AM EST NGM Bio Announces Clinical Trial Collaboration With Merck Related To Ongoing Phase 1/2 Trial Of NGM707 In Combination With Merck's KEYTRUDA Benzinga

08:00AM EST NGM Bio Announces Clinical Trial Collaboration with Merck Related GlobeNewswire Inc

Nov 9, 2021

06:30AM EST NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the following upcoming 2021 virtual investor conferences: GlobeNewswire Inc

Nov 5, 2021

10:41AM EDT Raymond James Maintains Strong Buy on NGM Biopharmaceuticals, Raises Price Target to $42 Benzinga

09:28AM EDT NGM Biopharmaceuticals Q3 EPS $(0.37) Up From $(0.43) YoY, Sales $18.57M Down From $23.48M YoY Benzinga

Sep 17, 2021

07:39AM EDT 10 Biggest Price Target Changes For Friday Benzinga

07:09AM EDT BMO Capital Maintains Outperform on NGM Biopharmaceuticals, Raises Price Target to $35 Benzinga

Sep 16, 2021

08:05AM EDT NGM Bio Highlights Presentation Of Preliminary Findings from Ongoing Phase 1a/1b Dose Escalation Study Of NGM120 In Patients With Advanced Solid Tumors At ESMO Virtual Congress 2021 Benzinga

08:01AM EDT NGM Bio Presents Preliminary Findings from Ongoing Phase 1a/1b GlobeNewswire Inc

Sep 13, 2021

10:18AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2021 Benzinga

07:59AM EDT 10 Biggest Price Target Changes For Monday Benzinga

04:51AM EDT Raymond James Upgrades NGM Biopharmaceuticals to Strong Buy, Raises Price Target to $39 Benzinga

Aug 23, 2021

08:01AM EDT NGM Bio Discloses Fourth Oncology Development Candidate, NGM831 Benzinga

Aug 6, 2021

12:17PM EDT Raymond James Maintains Outperform on NGM Biopharmaceuticals, Raises Price Target to $27 Benzinga

Aug 5, 2021

04:36PM EDT NGM Biopharmaceuticals Q2 EPS $(0.48) Down From $(0.38) YoY, Sales $16.77M Down From $19.75M YoY Benzinga

Jul 23, 2021

07:45AM EDT The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs Benzinga

Jul 22, 2021

04:18PM EDT NGM Announces Completion Of Enrollment In Phase 2 CATALINA Study Of NGM621 In Patients With Geographic Atrophy Secondary To Age-Related Macular Degeneration Benzinga

04:05PM EDT NGM Announces Completion of Enrollment in Phase 2 CATALINA Study GlobeNewswire Inc

Jul 7, 2021

07:23AM EDT NGM Bio Begins Phase 1/2 Clinical Study Of NGM707 For Advanced Solid Tumors RTTNews

07:06AM EDT NGM Bio Announces Initiation Of Phase 1/2 Clinical Study Of NGM707 For Treatment Of Advanced Solid Tumors Benzinga

07:00AM EDT --NGM707, a ILT2/ILT4 dual antagonistic antibody, is engineered to reverse myeloid suppression with the goal of improving patient immune responses to tumors-- GlobeNewswire Inc

Jul 1, 2021

01:50PM EDT NGM Biopharma, Merck Amend Development Pact To Focus On Retinal, Cardiovascular & Metabolic Targets Benzinga

07:02AM EDT NGM Amends Collaboration with Merck to Focus Primarily on Advancing Novel Medicines for Retinal and Cardiovascular and Metabolic (CVM) Diseases Benzinga

07:00AM EDT NGM Amends Collaboration with Merck to Focus Primarily on GlobeNewswire Inc

Jun 7, 2021

08:00AM EDT NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at two upcoming investor conferences. GlobeNewswire Inc

Jun 4, 2021

09:35AM EDT NGM Biopharmaceuticals Publishes Clinical Trial Titled 'Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies' To ClinicalTrials.Gov Benzinga

May 24, 2021

02:40PM EDT Analyst Reactions on NGM Biopharmaceuticals Disappointing Aldafermin Data in NASH Study Benzinga

02:31PM EDT Mid-Afternoon Market Update: Dow Jumps 250 Points; Scopus BioPharma Shares Spike Higher Benzinga

12:15PM EDT Mid-Day Market Update: Crude Oil Rises 2.5%; NGM Biopharmaceuticals Shares Plunge Benzinga

11:44AM EDT Raymond James Downgrades NGM Biopharmaceuticals to Outperform, Lowers Price Target to $22 Benzinga

11:25AM EDT NGM Biopharmaceuticals Shares Quiet; Hearing Raymond James Downgrades Stock Benzinga

10:13AM EDT Mid-Morning Market Update: Markets Open Higher; Xeris Pharmaceuticals To Acquire Strongbridge Biopharma Benzinga

07:50AM EDT NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study Benzinga

07:02AM EDT NGM Biopharma Announces its Phase 2b ALPINE 2/3 Study of Aldafermin in NASH Did Not Meet its Primary Endpoint, Will Not Pursue Phase 3 Clinical Development of Aldafermin in F2/F3 Benzinga

07:00AM EDT NGM Bio Reports Topline Results from 24-Week Phase 2b ALPINE 2/3 GlobeNewswire Inc

06:57AM EDT NGM Biopharmaceuticals Shares Halted, News Pending Benzinga

06:39AM EDT NGM Biopharma to Release Mid-Stage NASH Data Monday: What to Expect? Benzinga

May 23, 2021

06:41PM EDT NGM Bio to Host Conference Call to Discuss Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH on Monday May 24 Benzinga

06:00PM EDT NGM Bio to Host Conference Call to Discuss Topline Results from GlobeNewswire Inc

May 6, 2021

05:01PM EDT NGM Biopharmaceuticals Q1 EPS $(0.36) Down From $(0.28) YoY, Sales $21.57M Down From $24.36M YoY Benzinga

Apr 28, 2021

04:15PM EDT NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced todaythe nomination of Roger M. Perlmutter, M.D., Ph.D., to stand for election to the companys board of directors at its June 8, 2021 annual meeting of stockholders. GlobeNewswire Inc

Mar 18, 2021

08:16AM EDT The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq Benzinga

Mar 5, 2021

08:09AM EST Chardan Capital Maintains Buy on NGM Biopharmaceuticals, Raises Price Target to $44 Benzinga

07:23AM EST Raymond James Maintains Strong Buy on NGM Biopharmaceuticals, Raises Price Target to $52 Benzinga

Mar 4, 2021

04:26PM EST NGM Biopharmaceuticals Q4 EPS $(0.40) Down From $(0.24) YoY, Sales $19.77M Down From $31.08M YoY Benzinga

04:05PM EST NGM Bio Provides Business Highlights and Reports Fourth Quarter GlobeNewswire Inc

Mar 2, 2021

08:22AM EST NGM Biopharma Reports Initiation Of Its Expansion Of Ongoing Phase 1b Proof-Of-Concept Study Of NGM120 In Patients With Metastatic Pancreatic Cancer Benzinga

08:01AM EST --Placebo-controlled study to evaluate potential of NGM120, a novel inhibitor of GDF15/GFRAL pathway, totreat cancer and cancer-related cachexia-- GlobeNewswire Inc

Feb 25, 2021

08:00AM EST NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the Cowen 41st Annual Health Care Conference on Thursday, March 4, at 11:10 am ET. GlobeNewswire Inc

Feb 9, 2021

08:07AM EST NGM Bio Announces Upcoming Presentation of Phase 1 Study Of NGM621 In Patients With Geographic Atrophy At Angiogenesis, Exudation, And Denigration 2021 Benzinga

08:00AM EST --Humanized IgG1 monoclonal antibody engineered to potently inhibit complement C3, with the potential for extended every eight-week dosing-- GlobeNewswire Inc

Jan 12, 2021

04:05PM EST NGM Bio Outlines 2021 Strategic Priorities Across Its Three GlobeNewswire Inc

Jan 8, 2021

11:06AM EST Raymond James Maintains Strong Buy on NGM Biopharmaceuticals, Raises Price Target to $50 Benzinga

Jan 6, 2021

05:43AM EST NGM Bio PricedUpsized 4.6M Share Public Offering of Common Stock @$27/Share Benzinga

Jan 5, 2021

09:55PM EST NGM Bio Announces Pricing of Upsized $125.0 Million Public GlobeNewswire Inc

08:39AM EST The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data Benzinga

Jan 4, 2021

04:02PM EST NGM Biopharma Reports $100M Common Stock Offering Benzinga

04:01PM EST NGM Bio Announces Proposed Offering of Common Stock GlobeNewswire Inc

Dec 29, 2020

08:09AM EST The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica Benzinga

Dec 22, 2020

07:45AM EST The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes Benzinga

06:19AM EST NGM Biopharmaceuticals Awarded U.S. Patent 10,869,909 "Compositions and methods of use for treating metabolic disorders" Benzinga

Dec 15, 2020

07:52AM EST The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga

Dec 10, 2020

07:42AM EST The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations Benzinga

Dec 9, 2020

04:13PM EST NGM Discloses Third Oncology Development Candidate, NGM438 For Treatment Of Advanced Solid Tumors Benzinga

04:05PM EST NGM Discloses Third Oncology Development Candidate, NGM438, a GlobeNewswire Inc

Dec 8, 2020

08:04AM EST The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings Benzinga

Nov 25, 2020

07:35AM EST The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback Benzinga

Nov 24, 2020

08:13AM EST The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia Benzinga

Nov 16, 2020

12:05PM EST Event to showcase NGMs multi-therapeutic area pipeline,including its oncology portfolio and Geographic Atrophy and NASH programs GlobeNewswire Inc

Nov 13, 2020

08:07AM EST NGM Biopharma Reports Presentation Of Phase 1 Safety, Pharmacokinetics Data For NGM621 In Patients With Geographic Atrophy At American Academy Of Ophthalmology Virtual Benzinga

08:00AM EST --Single and multiple intravitreal injections of NGM621 appeared safe and well tolerated in first-in-human study, with no patients experiencing serious adverse events, drug-related AEs, intraocular inflammation or choroidal neovascularization-- GlobeNewswire Inc

07:40AM EST The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations Benzinga

Nov 12, 2020

04:14PM EST NGM Biopharmaceuticals Q3 EPS $(0.43) Down From $(0.17) YoY, Sales $23.48M Up From $21.57M YoY Benzinga

Nov 11, 2020

08:00AM EST NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at three upcoming investor conferences. GlobeNewswire Inc

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 5, 2020

08:21AM EST NGM Bio To Present Safety And Pharmacokinetics Data From Phase 1 Study Of NGM621 In Patients With Geographic Atrophy At American Academy Of Ophthalmology (AAO) 2020 Virtual Benzinga

Nov 4, 2020

08:00AM EST NGM Bio Announces Multiple Aldafermin Presentations at Upcoming GlobeNewswire Inc

Oct 19, 2020

07:04AM EDT NGM Expands Oncology Portfolio with First Immuno-Oncology Development Candidate, NGM707, a Novel Dual Antagonist Antibody Inhibiting ILT2 and ILT4 Benzinga

07:00AM EDT NGM Expands Oncology Portfolio with First Immuno-Oncology GlobeNewswire Inc

Aug 29, 2020

07:20AM EDT NGM Bio Presents Comprehensive Findings from 24-Week Phase 2 Study GlobeNewswire Inc

Aug 18, 2020

08:06AM EDT NGM Bio Announces Oral Plenary Presentation Of 24-Week Phase 2 Study Of Aldafermin In Patients With NASH At The Digital International Liver Congress 2020 Benzinga

08:00AM EDT NGM Bio Announces Oral Plenary Presentation of 24-Week Phase 2 GlobeNewswire Inc

Aug 13, 2020

07:02AM EDT Chardan Capital Maintains Buy on NGM Biopharmaceuticals, Lowers Price Target to $39 Benzinga

Aug 12, 2020

04:20PM EDT NGM Biopharmaceuticals Q2 EPS $(0.38) Down From $(0.13) YoY, Sales $19.75M Down From $25.34M YoY Benzinga

04:05PM EDT --Sustained progress across clinical development programs spanning liver,retinal and metabolic diseases and cancer-- GlobeNewswire Inc

Aug 3, 2020

09:32AM EDT Benzinga's Top Upgrades, Downgrades For August 3, 2020 Benzinga

Jul 31, 2020

01:24PM EDT Piper Sandler Initiates Coverage On NGM Biopharmaceuticals with Overweight Rating, Announces Price Target of $30 Benzinga

08:00AM EDT NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at two upcoming investor conferences. GlobeNewswire Inc

Jul 27, 2020

08:20AM EDT NGM Bio Begins Phase 2 CATALINA Study Of NGM621 In Patients With Geographic Atrophy Secondary To AMD RTTNews

08:08AM EDT NGM Bio Announces Initiation Of Phase 2 CATALINA Study Of NGM621 In Patients With Geographic Atrophy (GA) Secondary To Age-Related Macular Degeneration Benzinga

08:01AM EDT -- Multicenter, randomized, double-masked, sham-controlled study will evaluate safety and efficacy of intravitreal injections of NGM621 every four or eight weeks for 48 weeks -- GlobeNewswire Inc

Share